Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923048 | 1.00 | P2RX7 (0.48) | P2RX7ELANECA1CA2HPGD | |
| SCHEMBL31390581 | 0.76 | FKBP1A (0.48) | ELANEHPGDFKBP1A | |
| SCHEMBL16084964 | 0.76 | MCL1 (0.49) | P2RX7ELANECA1CA2HPGD | |
| SCHEMBL6787595 | 0.76 | MCL1 (0.49) | P2RX7ELANECA1CA2HPGD | |
| SCHEMBL26116158 | 0.74 | P2RX7 (0.43) | P2RX7ELANECA1CA2HPGD | |
| SCHEMBL14348086 | 0.73 | MMP1 (0.56) | P2RX7CA1CA2LMNAFKBP1A | |
| SCHEMBL31390578 | 0.73 | FKBP1A (0.45) | HPGDFKBP1A | |
| SCHEMBL2924800 | 0.72 | FKBP1A (0.45) | HPGDFKBP1A | |
| SCHEMBL2923458 | 0.72 | FABP7 (0.41) | LMNAFKBP1AMAPT | |
| SCHEMBL3312151 | 0.72 | KMT2A (0.39) | P2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1897879-A2 | 2,4,5 substituted piperidines as renin inhibitors | Speedel Experimenta AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | P2RX7 2898/4885ELANE 1100/4885CA1 4294/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | P2RX7 1480/4885ELANE 723/4885CA1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.